[A19-45] Ribociclib (breast cancer; combination with fulvestrant) - Addendum to Commission A19-06
Last updated 04.07.2019
Commission awarded on 27.05.2019 by the Federal Joint Committee (G-BA).
Patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Conclusion of dossier assessment A19-06 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V
|Ribociclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A19-06